Olumacostat glasaretil

• CAT Number: I008445
• CAS Number: 1261491-89-7
• Molecular Formula: C26H43NO7
• Molecular Weight: 481.63
• Purity: ≥95%
• Synonyms: Olumacostat glasaretil; DRM01B; DRM-01B; DRM 01B.;2-((2-ethoxy-2-oxoethyl)(methyl)amino)-2-oxoethyl 5-(tetradecyloxy)furan-2-carboxylate
• Target: Acetyl-CoA Carboxylase
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• InChI: InChI=1S/C26H43NO7/c1-4-6-7-8-9-10-11-12-13-14-15-16-19-32-25-18-17-22(34-25)26(30)33-21-23(28)27(3)20-24(29)31-5-2/h17-18H,4-16,19-21H2,1-3H3
• InChIKey: FYJLDICZGDFWKP-UHFFFAOYSA-N
• SMILES: O=C(C1=CC=C(OCCCCCCCCCCCCCC)O1)OCC(N(CC(OCC)=O)C)=O

Olumacostat glasaretil(CAT: I008445) is an acetyl-CoA carboxylase inhibitor. Acetyl-CoA carboxylase (ACC) is an enzyme involved in fatty acid synthesis, and inhibiting its activity can help regulate lipid metabolism. Olumacostat glasaretil specifically targets and inhibits the two isoforms of ACC, ACC1, and ACC2. By inhibiting ACC, it reduces the production of malonyl-CoA, a key intermediate in fatty acid synthesis, which ultimately leads to a decrease in fatty acid production. This mechanism of action makes olumacostat glasaretil a potential therapeutic option for conditions characterized by excessive sebum production, such as acne vulgaris.

Reference

1: Melnik BC. Olumacostat Glasaretil, a Promising Topical Sebum-Suppressing Agent
that Affects All Major Pathogenic Factors of Acne Vulgaris. J Invest Dermatol.
2017 Jul;137(7):1405-1408. doi: 10.1016/j.jid.2017.01.026. PubMed PMID: 28647025.

2: Hunt DW, Winters GC, Brownsey RW, Kulpa JE, Gilliland KL, Thiboutot DM,
Hofland HE. Inhibition of Sebum Production with the Acetyl Coenzyme A Carboxylase
Inhibitor Olumacostat Glasaretil. J Invest Dermatol. 2017 Jul;137(7):1415-1423.
doi: 10.1016/j.jid.2016.12.031. Epub 2017 Mar 1. PubMed PMID: 28259683.

3: Bissonnette R, Poulin Y, Drew J, Hofland H, Tan J. Olumacostat glasaretil, a
novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa,
multicenter, randomized, vehicle-controlled study. J Am Acad Dermatol. 2017
Jan;76(1):33-39. doi: 10.1016/j.jaad.2016.08.053. Epub 2016 Oct 28. PubMed PMID:
28029390.